Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review-Reference-Cited by-同舟云学术

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review

Published:2010-03-16 Issue:6 Volume:8 Page:1256-1265
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:

Author:

IORIO A.,HALIMEH S.,HOLZHAUER S.,GOLDENBERG N.,MARCHESINI E.,MARCUCCI M.,YOUNG G.,BIDLINGMAIER C.,BRANDAO L. R.,ETTINGSHAUSEN C. E.,GRINGERI A.,KENET G.,KNÖFLER R.,KREUZ W.,KURNIK K.,MANNER D.,SANTAGOSTINO E.,MANNUCCI P. M.,NOWAK-GÖTTL U.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1538-7836.2010.03823.x/fullpdf

Reference23 articles.

1. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B;Nilsson;J Intern Med,1992

2. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized;Astermark;Br J Haematol,1999

3. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy;Fischer;Haemophilia,2001

4. Paediatric care of the child with haemophilia;Ljung;Haemophilia,2002

5. Optimizing factor prophylaxis for the haemophilia population: where do we stand?;Blanchette;Haemophilia,2004

Cited by 250 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationship between mutations in severe hemophilia A and risk of inhibitor development: A large single-center study;Transfusion and Apheresis Science;2024-12

2. Comprehensive Screening of Genetic Variants in the Coding Region of F8 in Severe Hemophilia A Reveals a Relationship with Disease Severity in a Colombian Cohort;Life;2024-08-21

3. Acid Treatment of FVIII-Containing Plasma Samples Unmasks a Broad Spectrum of FVIII-Specific Antibodies in ELISA;Hämostaseologie;2024-07-15

4. The enchanting canvas of CAR technology: Unveiling its wonders in non-neoplastic diseases;Med;2024-06

5. Mutational landscape, inhibitor development, and health‐care burden in non‐severe haemophilia A: A single‐centre Australian experience;Haemophilia;2024-04-05